Epigenetic Reprogramming in Cancer
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
The demonstration of induced pluripotency and direct lineage conversion has led to remarkable insights regarding the roles of transcription factors and chromatin regulators in mediating cell state transitions. Beyond its considerable implications for regenerative medicine, this body of work is highly relevant to multiple stages of oncogenesis, from the initial cellular transformation to the hierarchical organization of established malignancies. Here, we review conceptual parallels between the respective biological phenomena, highlighting important interrelationships among transcription factors, chromatin regulators, and preexisting epigenetic states. The shared mechanisms provide insights into oncogenic transformation, tumor heterogeneity, and cancer stem cell models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [117]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells
Yu, J., Vodyanik, M. A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J. L., Tian, S., Nie, J., Jonsdottir, G. A., Ruotti, V., Stewart, R., et al. (2007) · Science · doi:10.1126/science.1151526 · Cited by 10,310
Dang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Expression of a single transfected cDNA converts fibroblasts to myoblasts
Davis, R. L., Weintraub, H., & Lassar, A. B. (1987) · Cell · doi:10.1016/0092-8674(87)90585-x · Cited by 3,385
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Loss of the Suv39h Histone Methyltransferases Impairs Mammalian Heterochromatin and Genome Stability
Peters, A. H. F. M., O'Carroll, D., Scherthan, H., Mechtler, K., Sauer, S., Schöfer, C., Weipoltshammer, K., Pagani, M., Lachner, M., Kohlmaier, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00542-6 · Cited by 1,766
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Cited by
Items 101–200 of 702
Persistently Altered Epigenetic Marks in the Mouse Uterus After Neonatal Estrogen Exposure
Jefferson, W. N., Chevalier, D. M., Phelps, J. Y., Cantor, A. M., Padilla‐Banks, E., Newbold, R. R., Archer, T., Kinyamu, H. K., & Williams, C. J. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1211 · Cited by 106
Tumour resistance in induced pluripotent stem cells derived from naked mole-rats
Miyawaki, S., Kawamura, Y., Oiwa, Y., Shimizu, A., Hachiya, T., Bono, H., Koya, I., Okada, Y., Kimura, T., Tsuchiya, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms11471 · Cited by 95
“The expression of many tumour suppressors, oncogenes and pluripotency genes, including Oct4, Sox2, Klf4 and c-Myc (OSKM), contributes to both reprogramming and oncogenesis 5,11 , and the transient in vivo expression of OSKM has been shown to induce tumours in certain tissues 12 .”
Fractal dimension of chromatin: potential molecular diagnostic applications for cancer prognosis
Metze, K. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.828889 · Cited by 99
Gopi, L. K., & Kidder, B. L. (2021) · Nature Communications · doi:10.1038/s41467-021-21707-1 · Cited by 123
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression
Bhatia, S., Wang, P., Toh, A. K. L., & Thompson, E. W. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00071 · Cited by 104
The genome-wide mutational consequences of DNA hypomethylation
Besselink, N. J. M., Keijer, J. P., Vermeulen, C., Boymans, S., de Ridder, J., van Hoeck, A., Cuppen, E. P. J. G., & Kuijk, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-33932-3 · Cited by 110
Targeted epigenome editing of an endogenous locus with chromatin modifiers is not stably maintained
Kungulovski, G., Nunna, S., Thomas, M., Zanger, U. M., Reinhardt, R., & Jeltsch, A. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0002-z · Cited by 92
“Epigenetic signaling is not only essential for normal development but it plays a central role in the onset of diseases including cancer as well [11-14].”
BackgroundEpigenetic reprogramming of melanoma cells by vitamin C treatment
Gustafson, C. B., Yang, C., Dickson, K. M., Shao, H., Van Booven, D., Harbour, J. W., Liu, Z.-J., & Wang, G. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0087-z · Cited by 90
“Recent discoveries of the epigenetic abnormalities in cancer provide unprecedented opportunities to reprogram malignant cancer cells and alter them toward healthy cells by targeting related enzymes that are responsible for the epigenetic modifications [21].”
Wu, B.-K., Mei, S.-C., Chen, E. H., Zheng, Y., & Pan, D. (2022) · Nature Genetics · doi:10.1038/s41588-022-01119-7 · Cited by 90
“7h); and (2) YAP-induced transcriptional activity of the methylated reporter was further reduced by TET1 knockdown (Extended Data Fig.”
BackgroundEpigenetic Remodeling Hydrogel Patches for Multidrug‐Resistant Triple‐Negative Breast Cancer
Ji, X., Guo, D., Ma, J., Yin, M., Yu, Y., Liu, C., Zhou, Y., Sun, J., Li, Q., Chen, N., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100949 · Cited by 88
Naked Mole Rat Cells Have a Stable Epigenome that Resists iPSC Reprogramming
Tan, L., Ke, Z., Tombline, G., Macoretta, N., Hayes, K., Tian, X., Lv, R., Ablaeva, J., Gilbert, M., Bhanu, N. V., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.10.001 · Cited by 88
“Furthermore, expression of the reprogramming genes Oct4, Sox2, Klf4, and c-Myc (OSKM) is frequently perturbed in cancer (Ben-David and Benvenisty, 2011; Suva et al., 2013).”
BackgroundhSETD1A Regulates Wnt Target Genes and Controls Tumor Growth of Colorectal Cancer Cells
Salz, T., Li, G., Kaye, F., Zhou, L., Qiu, Y., & Huang, S. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1400 · Cited by 89
“Alterations in histone modifications can drive important cancerous processes, such as proliferation, invasion, angiogenesis, and differentiation, by perturbing normal gene expression patterns (8, 9).”
BackgroundAMPK Promotes SPOP-Mediated NANOG Degradation to Regulate Prostate Cancer Cell Stemness
Wang, X., Jin, J., Wan, F., Zhao, L., Chu, H., Chen, C., Liao, G., Liu, J., Yu, Y., Teng, H., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.11.033 · Cited by 92
Ouyang, L., Yan, B., Liu, Y., Mao, C., Wang, M., Liu, N., Wang, Z., Liu, S., Shi, Y., Chen, L., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0181-3 · Cited by 92
Restoring tumor immunogenicity with dendritic cell reprogramming
Zimmermannová, O., Ferreira, A. G., Ascic, E., Santiago, M. V., Kurochkin, I., Hansen, M., Met, Ö., Caiado, I., Shapiro, I. E., Michaux, J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add4817 · Cited by 104
“endowed with epigenetic plasticity (13) that allows reversal or modification of cancer cell fate (14) by cellular reprogramming (15, 16).”
BackgroundThe role of epigenomics in personalized medicine
Kronfol, M. M., Dozmorov, M. G., Huang, R., Slattum, P. W., & McClay, J. L. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1284557 · Cited by 91
“of cancer epigenetics have been published recently [44,45], so here we limit ourselves to epigenetic marks in cancer showing”
BackgroundEpigenetic regulation of cancer stem cell formation and maintenance
French, R., & Pauklin, S. (2020) · International Journal of Cancer · doi:10.1002/ijc.33398 · Cited by 93
“Indeed CSCs possess a more plastic and dynamic chromatin formation than differentiated cells.(60) In AML CSCs, genes involved in stem cell”
BackgroundEpigenetic reprogramming in cancer: From diagnosis to treatment
Costa, P. M. S., Sales, S. L. A., Pinheiro, D. P., Pontes, L. Q., Maranhão, S. S., Pessoa, C., Furtado, G. P., & Furtado, C. L. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1116805 · Cited by 99
“The stem-like state or stem progenitor for cancer development is the major challenge in treatment, as it promotes unlimited self-renewal, multi-lineage differentiation and drug resistance (Suvà et al., 2013) Furthermore, alterations in the tumor microenvironment, tumor heterogeneity and regulation of stromal cells are…”
BackgroundThe stem cell division theory of cancer
López‐Lázaro, M. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.01.010 · Cited by 114
“All these DNA alterations have a marked effect on gene expression and are very common in cancer samples [37-41].”
BackgroundGevensleben, H., Holmes, E. E., Goltz, D., Dietrich, J., Sailer, V., Ellinger, J., Dietrich, D., & Kristiansen, G. (2016) · Oncotarget · doi:10.18632/oncotarget.13161 · Cited by 84
“Furthermore, DNA methylation is often deregulated in human malignancies [11-14] suggesting that aberrantly methylated loci might be a valuable source for biomarkers [15-16].”
BackgroundCancer cell reprogramming: a promising therapy converting malignancy to benignity
Gong, L., Yan, Q., Zhang, Y., Fang, X., Liu, B., & Guan, X. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0393-5 · Cited by 91
“There exists a large subpopulation of epigenetically blocked tumor suppressor genes in cancer cells [13, 20, 82].”
BackgroundInfluentialThe role of miR‐146a in viral infection
Nahand, J. S., Karimzadeh, M. R., Nezamnia, M., Fatemipour, M., Khatami, A., Jamshidi, S., Moghoofei, M., Taghizadieh, M., Hajighadimi, S., Shafiee, A., et al. (2019) · IUBMB Life · doi:10.1002/iub.2222 · Cited by 88
“The histone demethylase KDM2B is a significant regulator of the cell growth and can immortalize primary cells, and also contributes to the bypass of senescence in primary cells.(120) Furthermore, KDM2B induces the development of tumor and is implicated in leukemia, breast cancer, and pancreatic cancer.”
BackgroundMetabolism and Its Sequelae in Cancer Evolution and Therapy
Gillies, R. J., & Gatenby, R. A. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000102 · Cited by 86
“Mutations, chromosomal rearrangements, insertion/deletions (INDELs), and the whole host of epigenetic changes are all “mechanisms of inheritance” that can contribute to the cellular phenotype.(3,4) Diversity of these genetic alterations can contribute to phenotypic heterogeneity, although the relationship is nonlinear.”
BackgroundGCN5 acetyltransferase in cellular energetic and metabolic processes
Mutlu, B., & Puigserver, P. (2020) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2020.194626 · Cited by 88
“Acetyl-CoA acts as the building block for both lipogenesis and histone acetylation, key drivers of tumorigenesis [33,34].”
BackgroundMolecular Network of Colorectal Cancer and Current Therapeutic Options
Huang, Z., & Yang, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.852927 · Cited by 97
An essential role for UTX in resolution and activation of bivalent promoters
Dhar, S. S., Lee, S.-H., Chen, K., Zhu, G., Oh, W., Allton, K. L., Gafni, O., Kim, Y. Z., Tomoiga, A. S., Barton, M. C., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1516 · Cited by 79
“In addition, UTX is mutated in genetic diseases and multiple types of cancer (44).”
BackgroundCao, Y. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0188-9 · Cited by 94
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1
Cahill, D. P., Louis, D. N., & Cairncross, J. G. (2015) · CNS Oncology · doi:10.2217/cns.15.32 · Cited by 84
Feng, H., Yu, Z., Tian, Y., Lee, Y.-Y., Li, M. S., Go, M. Y. Y., Cheung, Y.-S., Lai, P. B. S., Chan, A. M. L., To, K.-F., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.040 · Cited by 75
“Numerous evidence have suggested that aberrations of EZH2 represent early events that render cells susceptible to oncogenic transformation and refractory to differentiation program [15, 16].”
BackgroundYang, H., Salz, T., Zajac‐Kaye, M., Liao, D., Huang, S., & Qiu, Y. (2014) · The FASEB Journal · doi:10.1096/fj.14-250654 · Cited by 84
“Altered expression of epigenetic factors is also involved in regulating cancer-relevant processes, including epithelial-to-mesenchymal transition (EMT), senescence, genome stability, and metastasis (4, 5).”
BackgroundThe Global Relationship between Chromatin Physical Topology, Fractal Structure, and Gene Expression
Almassalha, L. M., Tiwari, A., Ruhoff, P. T., Stypula‐Cyrus, Y., Cherkezyan, L., Matsuda, H., Cruz, M. D., Chandler, J. E., White, C., Maneval, C. D., et al. (2017) · Scientific Reports · doi:10.1038/srep41061 · Cited by 83
Poli, V., Fagnocchi, L., & Zippo, A. (2018) · Stem Cells International · doi:10.1155/2018/4598195 · Cited by 75
“more accessible, plastic, and hyperdynamic chromatin with respect to their differentiated counterparts [97].”
BackgroundDietrich, D., Jung, M., Pützer, S., Leisse, A., Holmes, E. E., Meller, S., Uhl, B., Schatz, P., Ivascu, C., & Kristiansen, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084225 · Cited by 76
“Methylation of the cytosine within the CpG dinucleotide context plays a key role in fundamental biological processes and human diseases and aberrant DNA methylation is a hallmark of human cancers [20,21,22,23].”
BackgroundMethodSmyd3-associated regulatory pathways in cancer
Giakountis, A., Moulos, P., Sarris, M. E., Hatzis, P., & Talianidis, I. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.08.008 · Cited by 88
Zheng, Y., Fornelli, L., Compton, P. D., Sharma, S., Canterbury, J., Mullen, C., Zabrouskov, V., Fellers, R. T., Thomas, P. M., Licht, J. D., et al. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.053819 · Cited by 73
“A pair of cell lines, TKO and NTKO, were engineered from a t(4;14) multiple myeloma patient-derived cell line, KMS11.”
BackgroundInfluentialSong, Y., Li, Z., Liu, X., Wang, R., Li, L.-W., & Zhang, Q. (2017) · Tumor Biology · doi:10.1177/1010428317712617 · Cited by 79
Epiproteomics: quantitative analysis of histone marks and codes by mass spectrometry
Zheng, Y., Huang, X., & Kelleher, N. L. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.06.007 · Cited by 71
“The large number of recurrent mutations identified in histone modifying enzymes has spurred great interest in cancer epigenetics [2].”
BackgroundSudemycin E influences alternative splicing and changes chromatin modifications
Convertini, P., Shen, M., Potter, P. M., Palacios, G. F., Lagisetti, C., de la Grange, P., Horbinski, C., Fondufe‐Mittendorf, Y. N., Webb, T. R., & Stamm, S. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku151 · Cited by 76
“Similar to stem cells, cancer cells have generally more dynamic chromatin, in part characterized by abundant H3K36me3 marks (38,39).”
BackgroundKodama, T., Newberg, J. Y., Kodama, M., Rangel, R., Yoshihara, K., Tien, J. C.-Y., Parsons, P. H., Wu, H., Finegold, M. J., Copeland, N. G., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1606876113 · Cited by 81
“Loss-of-function mutations of KDM6A are frequently observed in various human cancers, including bladder cancers, medulloblastomas, and renal cancers (59), suggesting that KDM6A functions as a tumor suppressor.”
BackgroundBartlett, T. E., Chindera, K., McDermott, J. R., Breeze, C. E., Cooke, W. R., Jones, A., Reisel, D., Karegodar, S. T., Arora, R., Beck, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms11620 · Cited by 80
Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq
Gerber, T., Willscher, E., Loeffler‐Wirth, H., Hopp, L., Schadendorf, D., Schartl, M., Anderegg, U., Camp, J. G., Treutlein, B., Binder, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13666 · Cited by 80
Molecular and genetic inflammation networks in major human diseases
Zhao, Y., Forst, C. V., Sayegh, C. E., Wang, I.-M., Yang, X., & Zhang, B. (2016) · Molecular BioSystems · doi:10.1039/c6mb00240d · Cited by 69
Zhang, Z., Lei, A., Xu, L., Chen, L., Chen, Y., Zhang, X., Gao, Y., Yang, X., Zhang, M., & Cao, Y. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.785865 · Cited by 88
Stem cell division theory of cancer
López‐Lázaro, M. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1062330 · Cited by 76
Dissecting human gliomas by single-cell RNA sequencing
Tirosh, I., & Suvà, M. L. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox126 · Cited by 78
Self-citationSonnenschein, C., Soto, A. M., Rangarajan, A., & Kulkarni, P. (2014) · Journal of Biosciences · doi:10.1007/s12038-013-9403-y · Cited by 82
“Indeed, the importance of these mechanisms in the generation of intratumoral heterogeneity, in switching cell-fates during the process of epithelial-mesenchymal transitions associated with metastasis, in generating epithelial cell plasticity, and in determining the states of drug resistance and stemness, are increasin…”
BackgroundTP53 drives invasion through expression of its Δ133p53β variant
Gadéa, G., Arsic, N., Fernandes, K., Diot, A., Joruiz, S. M., Abdallah, S., Meuray, V., Vinot, S., Anguille, C., Reményi, J., et al. (2016) · eLife · doi:10.7554/elife.14734 · Cited by 74
“In particular, WT TAp53 a protein prevents cell migration and invasion which are the main traits of Epithelial to Mesenchymal Transition (EMT), which itself involves global genome reprogramming that drives cancer progression to metastasis ( McDonald et al., 2011 ; Suva et al., 2013 ).”
Tan, E.-J., Kahata, K., Idås, O., Thuault, S., Heldin, C.-H., & Moustakas, A. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1293 · Cited by 68
“Alterations of the epigenome occur during cancer progression and the EMT process (24,25).”
Taube, J. H., Sphyris, N., Johnson, K. S., Reisenauer, K. N., Nesbit, T. A., Joseph, R., Vijay, G. V., Sarkar, T. R., Bhangre, N., Song, J. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19214 · Cited by 75
Application of histone modification-specific interaction domains as an alternative to antibodies
Kungulovski, G., Kycia, I., Tamas, R., Jurkowska, R. Z., Kudithipudi, S., Henry, C., Reinhardt, R., Labhart, P., & Jeltsch, A. (2014) · Genome Research · doi:10.1101/gr.170985.113 · Cited by 76
“These PTMs regulate a multitude of chromatin-templated transactions, play a central role in development, and are implicated inmany diseases, such as cancer (Suva et al. 2013).”
BackgroundBoulay, G., Awad, M. E., Riggi, N., Archer, T. C., Iyer, S., Boonseng, W. E., Rossetti, N. E., Naigles, B., Rengarajan, S., Volorio, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0844 · Cited by 81
Self-citationSOX17 in cellular reprogramming and cancer
Tan, D. S., Holzner, M., Weng, M., Srivastava, Y., & Jauch, R. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.008 · Cited by 64
Mehta, S., Cronkite, D. A., Basavappa, M. G., Saunders, T. L., Adiliaghdam, F., Amatullah, H., Morrison, S. A., Pagan, J. D., Anthony, R. M., Tonnerre, P., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aag3160 · Cited by 73
Varum, S., Baggiolini, A., Zurkirchen, L., Atak, Z. K., Cantù, C., Marzorati, E., Bossart, R., Wouters, J., Häusel, J., Tuncer, E., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.03.011 · Cited by 65
Lee, S.-H., Chen, T., Dhar, S. S., Gu, B., Chen, K., Kim, Y. Z., Li, W., & Lee, M. G. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw788 · Cited by 73
“Several pluripotent factors are associated with oncogenic events (41).”
BackgroundTargeting Chromatin Remodeling for Cancer Therapy
Kaur, J., Daoud, A., & Eblen, S. T. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666190215112915 · Cited by 73
Penter, L., Gohil, S. H., Lareau, C. A., Ludwig, L. S., Parry, E. M., Huang, T., Li, S., Zhang, W., Livitz, D. G., Leshchiner, I., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0276 · Cited by 68
Oxygen nanobubbles revert hypoxia by methylation programming
Bhandari, P. N., Cui, Y., Elzey, B. D., Goergen, C. J., Long, C. M., & Irudayaraj, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-08988-7 · Cited by 66
Rinaldi, G., Rossi, M., & Fendt, S. (2018) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1397 · Cited by 63
“The best described epigenetic marks are DNA as well as histone methylation and histone acetylation.(100,101) In humans, DNA methylation of cytosine residues in CpG islands in promoter regions is commonly associated with transcriptional inhibition.”
BackgroundTurinetto, V., Orlando, L., & Giachino, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091952 · Cited by 64
“Cellular reprogramming is a rare, multi-step process, which shares many biological and molecular pathways with tumorigenesis [55].”
BackgroundThe role of epigenetic therapies in colorectal cancer
Baretti, M., & Azad, N. S. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.03.001 · Cited by 66
Reprogramming of human cancer cells to pluripotency for models of cancer progression
Kim, J., & Zaret, K. S. (2015) · The EMBO Journal · doi:10.15252/embj.201490736 · Cited by 67
“Pluripotent ES cells and iPS cells have epigenetic features that may be reciprocal to those in cancer cells (Suva et al , 2013).”
Armas‐López, L., Zúñiga, J., Arrieta, O. G., & Ávila‐Moreno, F. (2017) · Oncotarget · doi:10.18632/oncotarget.19527 · Cited by 69
“Based on this, transcriptional programming events and epigenetic reprogramming mechanisms actively intervene in erasing and writing DNA methylation patterns, as well as in the modification of histone codes through diverse embryo stages such as gastrulation and late embryonic development periods and postnatally; as suc…”
BackgroundMeter, R. J. V., Glinski, D. A., Purucker, S. T., & Henderson, W. M. (2017) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2017.12.175 · Cited by 64
“E PA A uthor M anuscript E PA A uthor M anuscript E PA A uthor M anuscript proliferation in the body (e.g., Suva et al., 2013).”
BackgroundYu, O. M., Benitez, J. A., Plouffe, S. W., Ryback, D., Klein, A., Smith, J., Greenbaum, J., Delatte, B., Rao, A., Guan, K.-L., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0301-5 · Cited by 62
“54 The number of cells needed to form neurospheres was more than doubled when either YAP or MRTF-A were deleted (1/stem cell frequency increased from 20.9 to between 48.5 and 51.6 for YAP and MRTF-A knockdown, respectively).”
InfluentialZhan, X., Guo, S., Li, Y., Ran, H., Huang, H., Mi, L., Wu, J., Wang, X., Xiao, D., Chen, L., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191340 · Cited by 62
“It is well established that histone acetylation andmethylation play critical roles in regulating gene expression during stem cell differentiation (Easwaran et al., 2014; Mack et al., 2016; Suvà et al., 2013).”
BackgroundSheng, Y., Wang, H., Liu, D., Zhang, C., Deng, Y., Yang, F., Zhang, T., & Zhang, C. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.11.017 · Cited by 62
“Molecularly, accumulating evidence suggests that epigenetic changes are the major event in transformation of normal cells to cancers and promoter hypermethylation of tumor suppressor genes is an epigenetic hallmark of human cancer [5–7].”
BackgroundInhibition and Mechanism of HDAC8 Revisited
Chen, K., Zhang, X., Wu, Y.-D., & Wiest, O. (2014) · Journal of the American Chemical Society · doi:10.1021/ja501548p · Cited by 61
Developing DNA methylation-based diagnostic biomarkers
Kim, H.-R., Wang, X., & Jin, P. (2018) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2018.02.003 · Cited by 69
“…diseases, such as cancers and neurological disorders, the feasibility of DNA methylation assay for diagnosis has been reviewed through clinical studies (Esteller, 2008; Heyn and Esteller, 2012; Nikolaidis et al., 2012; Van Neste et al., 2012; Suva et al., 2013; Haggarty, 2015; Hwang et al., 2017).”
InfluentialKumari, R., Deshmukh, R. S., & Das, S. (2019) · Nature Communications · doi:10.1038/s41467-019-12194-6 · Cited by 60
Li, F., Zeng, J., Gao, Y., Guan, Z., Ma, Z., Shi, Q., Du, C., Jia, J., Xu, S., Wang, X., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138390 · Cited by 62
“It has been regarded as hallmarks of the initiation of tumorigenesis and aberrant epigenetic modifications have been considered to be pivotal mechanisms in the regulation of cell phenotypes[42].”
BackgroundSchmidt, B., Beyer, J., Dietrich, D., Bork, I., Liebenberg, V., & Fleischhacker, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118195 · Cited by 63
“As such, DNA methylation regulates gene transcription and epigenetic alterations in oncogenes and tumor suppressor genes and are of key importance to cancer development [14].”
BackgroundLi, A., You, D., Li, W., Cui, Y., He, Y., Li, W., Chen, Y., Feng, X., Sun, S., Chai, R., et al. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1461277 · Cited by 57
“Epigenetic mechanisms regulate the structure and activity of the genome in response to intracellular and environmental cues that direct cell type-specific gene networks and control cell development and survival (Weaver et al., 2004; Suva et al., 2013; Layman & Zuo, 2014; Roidl & Hacker, 2014).”
BackgroundEpigenetic modifications as regulatory elements of autophagy in cancer
Sui, X., Zhu, J., Zhou, J., Wang, X., Li, D., Han, W., Fang, Y., & Pan, H. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.009 · Cited by 63
The epigenetics of tumour initiation: cancer stem cells and their chromatin
Avgustinova, A., & Benitah, S. A. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.003 · Cited by 58
Cell Fate Reprogramming in the Era of Cancer Immunotherapy
Zimmermannova, O., Caiado, I., Ferreira, A. G., & Pereira, C.-F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714822 · Cited by 56
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells
Park, S.-M., Miyamoto, D. K., Han, G. Y. Q., Chan, M., Curnutt, N. M., Tran, N. L., Velleca, A., Kim, J. H., Schurer, A., Chang, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.010 · Cited by 56
Jia, J., Shi, Y., Chen, L., Lai, W., Yan, B., Jiang, Y., Xiao, D., Xi, S., Cao, Y., Liu, S., et al. (2017) · Theranostics · doi:10.7150/thno.21389 · Cited by 59
“DNA methylation is a crucial factor of epigenetics and plays a critical part in the development of several malignancies [28, 29], but its role in the progress of metastasis remains unknown.”
Saha, N., & Muntean, A. G. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188498 · Cited by 56
Ullius, A., Luscher-Firzlaff, J., Costa, I. G., Walsemann, G., Forst, A. H., Gusmao, E. G., Kapelle, K., Kleine, H., Kremmer, E., Vervoorts, J., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku312 · Cited by 57
“ASH2L was of interest to us because it has been described as a component of KMT2 group MTase complexes (14,58,59).”
BackgroundEnzymology of Mammalian DNA Methyltransferases
Jurkowska, R. Z., & Jeltsch, A. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43624-1_5 · Cited by 69
Cellular plasticity in reprogramming, rejuvenation and tumorigenesis: a pioneer TF perspective
Huyghe, A., Trajkova, A., & Lavial, F. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2023.07.013 · Cited by 56
Epigenetic susceptibility factors for prostate cancer with aging
Damaschke, N., Yang, B., Bhusari, S. S., Svaren, J. P., & Jarrard, D. F. (2013) · The Prostate · doi:10.1002/pros.22716 · Cited by 63
“Changing epigenetic marks modulate chromatin structure, and alter gene expression without the requirement for changing DNA sequence [6].”
Computational identification of specific genes for glioblastoma stem-like cells identity
Fiscon, G., Conte, F., Licursi, V., Nasi, S., & Paci, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-26081-5 · Cited by 58
“Many of the up-regulated TFs may function as oncogenes by enhancing developmental programs required for tumorigenesis 45 .”
BackgroundOsaki, M., Okada, F., & Ochiya, T. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.122 · Cited by 56
Metabolic interactions with cancer epigenetics
Gao, X., Reid, M. A., Kong, M., & Locasale, J. W. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.09.001 · Cited by 56
“Changes in the epigenetic landscape have become evident in many pathophysiological conditions including cancer and diabetes (Baylin and Jones, 2011; Feinberg and Tycko, 2004; Suva et al., 2013).”
Fritz, A. J., Ghule, P. N., Boyd, J. R., Tye, C. E., Page, N. A., Hong, D., Shirley, D. J., Weinheimer, A., Barutcu, A. R., Gerrard, D. L., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25996 · Cited by 58
Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells
Aztopal, N., Erkısa, M., Ertürk, E., Ulukaya, E., Tokullugil, A., & Arı, F. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.12.003 · Cited by 58
“Epigenetic reprogramming plays a crucial role in the regulation of stemness and tumorigenicity that especially occurs through the DNA methylation and/or histone modifications, as well-defined mechanisms [7].”
BackgroundTarget specificity of mammalian DNA methylation and demethylation machinery
Ravichandran, M., Jurkowska, R. Z., & Jurkowski, T. P. (2018) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob02574b · Cited by 70
Structural and Functional Overview of TEAD4 in Cancer Biology
Chen, M., Huang, B., Zhu, L., Chen, K., Liu, M., & Zhong, C. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266649 · Cited by 60
Chromatin structure in double strand break repair
Gospodinov, A. G., & Herceg, Z. (2013) · DNA repair · doi:10.1016/j.dnarep.2013.07.006 · Cited by 68
Activity and specificity of the human SUV39H2 protein lysine methyltransferase
Schuhmacher, M. K., Kudithipudi, S., Kušević, D., Weirich, S., & Jeltsch, A. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.11.005 · Cited by 60
Ruiz-Magaña, M. J., Martínez-Aguilar, R., Lucendo, E., Campillo-Davó, D., Schulze‐Osthoff, K., & Ruiz‐Ruiz, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7871 · Cited by 53
“In particular, silencing of tumor suppressor genes by promoter hypermethylation has been described in a variety of human solid tumors such as lung, colorectal, breast, gastric, endometrial and bladder tumors, as well as in hematopoietic malignancies [1-3], contributing to clonal expansion of malignant cells.”
BackgroundLei, A., Chen, L., Zhang, M., Yang, X., Xu, L., Cao, N., Zhang, Z., & Cao, Y. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00422 · Cited by 67
Patel, J., Baranwal, S., Love, I. M., Patel, N. J., Grossman, S. R., & Patel, B. B. (2014) · Cell Cycle · doi:10.4161/15384101.2014.958407 · Cited by 59
“Although the precise mechanisms governing stem cell self-renewal are poorly understood, it is widely accepted that epigenetic modulation of gene expression programs regulates stem cell fate.(7) Hypoxia, which promotes a reduced redox state (decreased oxidized nicotinamide adenosine dinucleotide [NAD] i.”
BackgroundLineage-restricted function of the pluripotency factor NANOG in stratified epithelia
Piazzolla, D., Palla, A. R., Pantoja, C., Cañamero, M., de Castro, I. P., Ortega, S., Goméz-López, G., Domínguez, O., Megías, D., Roncador, G., et al. (2014) · Nature Communications · doi:10.1038/ncomms5226 · Cited by 59
The DNMT1-associated lincRNA DACOR1 reprograms genome-wide DNA methylation in colon cancer
Somasundaram, S., Forrest, M. E., Moinova, H., Cohen, A., Varadan, V., LaFramboise, T., Markowitz, S. D., & Khalil, A. M. (2018) · Clinical Epigenetics · doi:10.1186/s13148-018-0555-3 · Cited by 57
The prognostic potential of alternative transcript isoforms across human tumors
Trincado, J. L., Sebestyén, E., Pagés, A., & Eyras, E. (2016) · Genome Medicine · doi:10.1186/s13073-016-0339-3 · Cited by 54
“Although tumors originate primarily from genetic lesions, their progression involves other molecular transformations, which are related to the activation of specific aggressive phenotypes, like tumor spread and metastasis, and are often reflected in gene expression changes [4, 5].”
BackgroundStructure, Activity and Function of the Suv39h1 and Suv39h2 Protein Lysine Methyltransferases
Weirich, S., Khella, M. S., & Jeltsch, A. (2021) · Life · doi:10.3390/life11070703 · Cited by 64
“In addition, aberrant histone PTMs are implicated in many diseases, such as cancer [5,6].”
BackgroundRole of somatic cancer mutations in human protein lysine methyltransferases
Kudithipudi, S., & Jeltsch, A. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.08.002 · Cited by 59
Metadata
- Authors
- Suvà, M. L., Riggi, N., & Bernstein, B. E.
- Affiliations
- Broad Institute (US)
- Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
- Corresponding author
- Suvà, Mario L.
- Bernstein, Bradley E.
- Venue
- Science
- Published
- 2013-03-29
- Volume
- 339
- Issue
- 6127
- Pages
- 1567-1570
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3821556
- OpenAlex
- W2090757807
- Cited by
- 706
- References
- 64
- Citations by year
- 2026: 13 · 2025: 26 · 2024: 19 · 2023: 40 · 2022: 34 · 2021: 61 · 2020: 62 · 2019: 48 · 2018: 58 · 2017: 72 · 2016: 67 · 2015: 76 · 2014: 85 · 2013: 43
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institute of Environmental Health Sciences (U01ES017155)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- epigenetic reprogramming, cancer, induced pluripotency, transcription factors, chromatin regulators, oncogenic transformation, tumor heterogeneity, cancer stem cells, cell state transitions
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Chromatin, Humans, Neoplasms, Transcription Factors, Neoplastic Stem Cells, DNA Methylation, Pluripotent Stem Cells, Epigenesis, Genetic, Mice, Cellular Reprogramming
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.